http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020055941-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5095f60dee8e6d7c3faa7cca7b58c08
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
filingDate 2018-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9acfe10eb54c11ffd6106be3ed76c233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e1dc4460b0bf33d3384081943e08a3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c01b27137fd01328c18993e2b1334d09
publicationDate 2020-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2020055941-A1
titleOfInvention POLYPEPTIDES WITH MUTANT HUMAN IgG4
abstract The present invention relates to polypeptides comprising a mutant human IgG 4 , which mutant human IgG 4 is capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing FcγRIIb/c (CD32b), but not FcγRIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgG 4 with a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgG 4 is capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgG 1 and than a wild-type human IgG 4 , for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021188631-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11701387-B2
priorityDate 2017-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004110226-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4199023
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID124886
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399016
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71068
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41206
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID745
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400643
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400160
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400161
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3440
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400532
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408690
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408691

Total number of triples: 41.